Cellares
Chemicals & Related Products · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
345 Allerton Ave, South San Francisco, C...Phone Number
(833) 235-5273Website
www.cellares.comRevenue
$94.2 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Cellares
Cellares is an Integrated Development and Manufacturing Organization (IDMO) focused on the automated, large-scale manufacture of cell therapies. The company provides global biopharmaceutical partners with development and commercial manufacturing services designed to address the capacity, consistency, and cost limitations of traditional, labor-intensive production models. Cellares operates fully automated manufacturing and quality control platforms Cell Shuttle for end-to-end cell therapy manufacturing and Cell Q for automated in-process and release testing across its network of IDMO Smart Factories. These cGMP-compliant systems enable higher process reproducibility, improved manufacturing success rates, and up to approximately 10 higher throughput compared to conventional CDMO approaches with similar footprint and headcount. Headquartered in South San Francisco, California, Cellares operates a commercial-scale Smart Factory in Bridgewater, New Jersey, with additional facilities under cRead more
Cellares Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cellares your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Cellares had a recent Job posting/layoffs
Check out if Cellares is spiking on competitors!
Earning: See what the market has to say on Cellares recently announced quarterly report
Check if Cellares has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Cellares
Website visits: Recent activity has been detected on your website
Cellares, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Cellares launches new products
Funding: Get notified immidiatlly once Cellares has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Cellares
Compare insights from companies similar to Cellares, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cellares is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Cellares is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Cellares.
Cellares financials insights
Gather financial insights about Cellares, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$18M
2021
Series B
$82M
2023
Series C
$255M
2026
Series D
$257M
Series D
$50M
Cellares Tech Stack
A closer look at the technologies used by Cellares
Most Recent Scoops
Open Position
Open Position
Person-Based
Pharmaceuticals, Manufacturing Operations
Open Position
Open Position
Cellares News & Media
Bristol-Myers Squibb (BMY)’s Cellares Exit Raises Questions Over Breyanzi Growth
Bristol-Myers Squibb Company (NYSE:BMY) has ended its partnership with cell-therapy manufacturer Cellares after determining that Cellares’ Cell Shuttle platform could not meet the requirements needed to manufacture Breyanzi at commercial scale. The partnership, announced in 2024, was valued at up to $380 million and was intended to expand Breyanzi manufacturing capacity across the U.S., Europe, […]Cellares CEO seeks to 'resize' company after loss of 'large' cell therapy manufacturing customer
With its ascent seemingly unstoppable in the last few years, automated cell therapy manufacturer Cellares is facing some tough new realities. | With its ascent seemingly unstoppable in the last few years, automated cell therapy manufacturer Cellares is facing some tough new realities.Cellares, a cell therapy manufacturing specialist, to lay off 100 employees
The restructuring comes after an unnamed "large pharmaceutical customer" terminated a contract with the company, Cellares CEO Fabian Gerlinghaus posted on LinkedIn.Cellares and Papillon partner for PPL-001 manufacturing automation
Under the collaboration, Cellares will adapt the PPL-001 manufacturing process for its Cell Shuttle platform.
Read more news
Top Chemicals & Related Products Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cellares
Sign Up For FreeTo access detailed company insights
Cellares is an Integrated Development and Manufacturing Organization (IDMO) focused on the automated, large-scale manufacture of cell therapies. The company provides global biopharmaceutical partners with development and commercial manufacturing services designed to address the capacity, consistency, and cost limitations of traditional, labor-inten... Read More
